- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01011920
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma
This is a multicenter open label randomized phase II trial.
Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary chemotherapy:
- Arm A: Methotrexate (MTX) + Cytarabine (Ara-C)
- Arm B: MTX + Ara-C + rituximab
- Arm C: MTX + Ara-C + rituximab + thiotepa.
Chemotherapy will be administered every three weeks. The maximum number of chemotherapy induction courses will be 4. Patients in Stable Disease (SD) or better after two courses will receive two more courses of the same primary chemotherapy regimen. Stem-cells harvest will be performed in the three arms after the second course. After 4 courses response assessment will be performed.
Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time and those who will not achieve a sufficient stem cell harvest, will receive Whole Brain Radiation Therapy (WBRT) 36-40 Gy +/- tumor bed boost of 9 Gy.
Patients who will achieve SD or better after the 4th course will be stratified according to objective response to primary chemotherapy and to primary chemotherapy regimen and randomly allocated to receive as consolidation therapy one of the follows:
- Arm D: WBRT 36 Gy +/- boost 9 Gy
- Arm E: Carmustine (BCNU) + Thiotepa + Autologous Peripheral Blood Stem Cell Transplant (APBSCT) Patients in Complete Response (CR) after WBRT or APBSCT will remain in follow-up. Patients who will not achieve a CR after WBRT will be managed according to physician's preferences. Patients who will not achieve a CR after APBSCT will be referred to WBRT.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany
- University Hospital
-
Erlangen, Germany
- Universitätsklinikum Erlangen
-
Essen, Germany
- "Klinik für Hämatologie Universitätsklinikum Essen"
-
Freiburg, Germany
- Uniklinik Freiburg
-
Hamburg, Germany
- Universitatskrankenhaus Hamburg-Eppendorf
-
Jena, Germany
- Friedrich Schiller Universitaet Jena
-
Mainz, Germany
- Johannes Gutenberg Universitat Mainz
-
München, Germany
- Technische Universität in München
-
Ulm, Germany
- Universitätsklinikum Ulm
-
-
-
-
-
Alessandria, Italy
- A.O. SS. Antonio e Biagio e Cesare Arrigo
-
Brescia, Italy
- Spedali Civili
-
Milan, Italy
- San Raffaele H Scientific Institute
-
Nocera Inferiore, Italy
- Ospedale Umberto I
-
Pescara, Italy
- Ospedale Civile S.Spirito
-
Reggio Emilia, Italy
- Arcispedale Santa Maria Nuova
-
Roma, Italy
- Istituto Nazionale dei Tumori Regina Elena
-
Roma, Italy
- Università degli Studi La Sapienza
-
Rozzano, Italy
- Humanitas
-
Torino, Italy
- Ospedale Maggiore S. Giovanni Battista
-
Verona, Italy
- Policlinico G.B. Rossi
-
-
-
-
-
Bellinzona, Switzerland, 6500
- IOSI - Oncology Institute of Southern Switzerland
-
-
-
-
-
Nottingham, United Kingdom
- Nottingham City Hospital
-
Romford, United Kingdom
- Queen's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma.
- Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid (CSF) cytology examination or vitrectomy.
- Disease exclusively localized into the central nervous system, CSF, cranial nerves or eyes.
- At least one measurable lesion.
- Previously untreated patients (previous or ongoing steroid therapy admitted).
- Age 18-65 years (with ECOG Performance Status 0-3) or 66-70 (with ECOG Performance Status 0-2).
- Adequate bone marrow, renal, cardiac, and hepatic function.
- Sexually active patients of childbearing potential agreeing in implementing adequate contraceptive measures during study participation.
- Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Patient-signed informed consent obtained before registration.
Exclusion Criteria:
- Patients with lymphomatous lesions outside the CNS.
- Patients with a previous non-Hodgkin lymphoma at any time.
- Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least from 5 years.
- HBsAg and HCV positivity.
- HIV infection, previous organ transplantation or other clinically evident form of immunodeficiency.
- Concurrent treatment with other experimental drugs.
- Concurrent Pregnancy or lactation.
- Patients not agreeing to take adequate contraceptive measures during the study.
- Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MTX+ AraC
Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min.
+ 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.)
d 2 - 3
|
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min.
+ 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
Other Names:
|
Experimental: Ara-C +Rituximab
Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min.
+ 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.)
d 2 - 3
|
Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
Other Names:
Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
Other Names:
|
Experimental: Ara-C + rituximab+thiotepa
Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min.
+ 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.)
d 2 - 3 Thiotepa 30 mg/m2 30 min.
Infusion d 4
|
Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
Other Names:
Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
Other Names:
ARM C: Thiotepa 30 mg/m2 (30 min.
Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf.
every 12 hrs days -5 & -4
|
Experimental: WBRT 36 Gy +/- boost 9 Gy
ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy.
Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
|
Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis).
Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
|
Experimental: BCNU + Thiotepa + APBSCT
Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf.
day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf.
every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
|
ARM C: Thiotepa 30 mg/m2 (30 min.
Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf.
every 12 hrs days -5 & -4
BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf.
day -6
Other Names:
Autologous peripheral blood stem cell transplant (APBSCT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate after primary chemotherapy and 2 years failure free survival at second randomization
Time Frame: 3 months, 2 years
|
3 months, 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety, as acute and long-term toxicity
Time Frame: Throughout all the active treatment period
|
Throughout all the active treatment period
|
overall survival
Time Frame: From entry onto trial until death for any cause
|
From entry onto trial until death for any cause
|
Collaborators and Investigators
Investigators
- Study Chair: Andrés JM Ferreri, MD, San Raffaele H Scientific Institute, Milan, Italy
- Study Chair: Gerald Illerhaus, MD, University Medical Center, Freiburg, Germany
- Principal Investigator: Emanuele Zucca, MD, IOSI, Bellinzona, Switzerland
Publications and helpful links
General Publications
- Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sonderskov Gorlov J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.
- Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosee PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Ruda R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gorlov JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Rituximab
- Cytarabine
- Methotrexate
- Thiotepa
- Carmustine
Other Study ID Numbers
- IELSG32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Central Nervous System Lymphoma | Central Nervous System B-Cell Non-Hodgkin Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Dana-Farber Cancer InstituteRecruitingRefractory Central Nervous System Lymphoma | Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaboratorsRecruitingPrimary Central Nervous System Hodgkin LymphomaChina
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedLymphoma, Non-Hodgkin | Central Nervous System NeoplasmsNorway
-
Institut CurieNational Cancer Institute, FranceRecruitingLymphoma, Large B-Cell, Diffuse | Central Nervous System Neoplasms, PrimaryFrance
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Vanderbilt-Ingram Cancer CenterBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Czech Lymphoma Study GroupUnknownDiffuse Large B-cell LymphomaCzech Republic